Comparison of Safety Profiles for Dapagliflozin Based on Safety Issues of EMA and FDA: Challenges and Future of Post-Marketing Surveillance in Korea

Author:

Park Suvin1,Kim Hee-Jin1,Won Heehyun1,Lee Huieon1,Cho Haerin1,Choi Nam-Kyong1

Affiliation:

1. Ewha Womans University

Abstract

Abstract Europe, the United States, and Korea each have post-marketing surveillance (PMS) systems for rare or unexpected adverse events (AEs). To compare similarities in the PMS AEs from three regulatory agencies, we used information on the regulatory decisions for dapagliflozin. We examined the risk management plan of the European Medicines Agency (EMA) and the drug label of the Food and Drug Administration (FDA). In Korea, we utilized the outcomes of the signal detection we conducted using the Korea Adverse Event Reporting System (KAERS) data and the results of the use-result surveillance listed on the drug labels. Based on the safety issues of EMA and FDA, signals from KAERS and AEs from the use-result surveillance were manually matched and compared. We compared 38 signals from KAERS and 231 AEs from the use-result surveillance data based on 17 safety issues identified by EMA and FDA. We found that 71% of these safety issues were consistent with those in Korea. However, bladder carcinoma, haematocrit increased, hypoglycaemia, low-density lipoprotein increased, and prostate cancer were not identified in Korea. The EMA and FDA have implemented ongoing PMS systems to identify and address long-term AEs. Korea needs to develop processes for strengthening and evaluating signals.

Publisher

Research Square Platform LLC

Reference24 articles.

1. Risk Management Plans: are they a tool for improving drug safety?;Frau S;Eur. J. Clin. Pharmacol.,2010

2. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA;Mofid S;Clin Ther,2022

3. Ministry of Food and Drug Safety (MFDS). Standard for Re-examination of New Drugs, etc. https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71517&srchFr=&srchTo=&srchWord=examination&srchTp=7&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1(2022).

4. Dapagliflozin: a review in type 2 diabetes;Dhillon S;Drugs.,2019

5. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Search Studies. https://www.encepp.eu/encepp/studySearch.htm

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3